secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213472
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs Q1 net loss $22.3M; positive Phase 1 data for BGE-102 NLRP3 inhibitor
--------------------------------------------------------------------------------

- Net loss $22.3M ($0.52 diluted EPS) vs $12.9M ($0.36) in Q1 2025; R&D spend rose to $20.4M.
- Positive Phase 1 data for oral NLRP3 inhibitor BGE-102: median hsCRP reduction 86%, 87-93% reached normalized hsCRP <2 mg/L.
- Ph2 dose-ranging trial in CVD risk and Ph1b/2a in diabetic macular edema both planned to start mid-2026.
- Cash, equivalents & securities $384.9M as of Mar 31, 2026; funded through 2029.
- Completed upsized follow-on offering for $132.3M in gross proceeds in early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/0001193125-26-213472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/bioa-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer